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Introduction
The recent advances in diagnostic imaging modalities and 
the widespread use of computed tomography (CT) scan 
resulted in increasing detection of ground glass opacities 
(GGOs) (1,2).
Many studies investigated the correlation between the 
radiologic findings of GGO lesions and their pathologic 
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diagnosis (3-5) demonstrating that GGO is a nonspecific 
finding caused by various disorders, including benign 
conditions such as inflammatory disease and focal fibrosis, 
atypical adenomatous hyperplasia (AAH), and malignant 
lesions such as adenocarcinoma in situ (AIS) and invasive 
adenocarcinoma (ADC). However, GGO lesions are also 
detected as multiple lesions, and/or in addition to an 
invasive ADC, representing a diagnostic and therapeutic 
challenge. The possibility of multifocal ADC cannot be 
ruled out without a pathological diagnosis that is not always 
possible especially when the lesions are located deeply in the 
hilum or many lesions are scattered in different lungs. Since 
biopsy or excision of these lesions is relatively difficult, 
these slow growing GGOs are currently considered for 
follow-up instead of definitive diagnosis or treatment (6-8). 
However, according to previous studies, the patient’s history 
of lung cancer increases the risk of evolution of GGOs 
(5,6,8). Only few studies (9-13) reported the natural history 
of multiple GGOs associated with primary lung cancer 
with controversial results and no consensus regarding their 
appropriate follow-up period and treatment strategy has 
been defined (5,9-11). In particular no standard criteria have 
been established for the selection of which lesion should 
be resected simultaneously with the main cancer (MC) and 
which could be initially followed up with serial CT without 
surgical resection. Moreover, almost all published data 
are derived from Asian countries and may not be reliably 
transferrable to a Caucasian population. 
The aim of this study was to evaluate the effect of first-
time and eventual reiterative surgery on overall survival (OS) 
and disease-free survival (DFS) in a population of Caucasian 
patients affected by a lung ADC with at least another 
nodule showing GGO appearance. We also analysed the 
behaviour of un-resected GGOs at first-time surgery and 
the development of new lesions in order to determine if the 
presence of additional GGOs influenced the prognosis and 
render the surgical therapy inappropriate for this clinical 
scenario.
Methods
We analysed the prospective maintained database of two 
affiliated tertiary centres (Thoracic Surgery Unit, University 
Hospital Careggi, Florence and Thoracic Surgery Unit, 
Siena University Hospital, Siena) about all patients operated 
on for lung ADC identified as MC, associated with at least 
one synchronous pure or predominately GGO nodule 
located in a different lobe or lung from January 2003 to 
March 2017. 
Pre-operative CT scans were reviewed to identify the 
subgroup of the patients who pre-operatively showed at least 
one separate, synchronous GGO lesion. Exclusion criteria 
were: presence of GGO in the same lobe of the MC (n=12); 
presence of uncountable GGOs (>10 nodules per patient) 
and patients with other synchronous completely solid 
nodules. The MC was defined as the lung lesion of larger 
diameter or that showing more radiologically invasiveness 
(margin of nodule, pleural indentation, presence of solid 
portion), while non-dominant nodules (NDNs) were any 
other non-calcified lung lesions radiologically evident. 
On the basis of its appearance on the thin-section CT 
scan, GGOs were classified as pure GGO (pGGO) lesions 
only if they had 100% GGO proportion and as part-solid 
(PSGGO) if a solid component was present. 
The surgical procedure was determined according 
to the site of the MC and NDN, patient comorbidities 
and respiratory function. Initial surgical treatment 
included removal of the MC and any accessible ipsilateral 
NDN. However, if the homolateral NDN was smaller 
than 10 mm, impalpable and/or deep-located into the 
parenchyma requiring an extensive lung resection (for 
example a pneumonectomy), we decided to perform a close 
radiological follow-up with CT. Non dominant GGOs 
being followed or the newly developed NDNs were treated 
with surgical resection or stereotactic body radiation 
therapy (SBRT) in case of progression, defined as growth of 
the GGO of at least 2 mm in diameter (6), development of 
a new solid component in a pGGO or enlargement of the 
solid component in PSGGO. 
Lung cancers were staged in accordance with the seventh 
edition of the TNM Classification for Lung and Pleural 
Tumours (14). ADC subtypes were defined according the 
2011 Guidelines of the International Association for the 
Study of Lung, American Thoracic Society and European 
Respiratory Society (15). Consequently, 47 patients (1.7%) 
among 2,668 patients operated on for NSCLC in the same 
period, fulfilled these criteria and form the study population. 
Their medical records were reviewed to evaluate the clinical 
characteristics, histopathologic findings, long term outcome 
and recurrence. All patients were regularly evaluated by CT 
scan every 3 months for the first 2 years after surgery and 
every 6 months thereafter.
Patient and tumour characteristics were analysed to 
identify factors associated with OS and DFS and GGO 
progression requiring a therapeutic intervention. 
Locoregional recurrence was defined as the development 
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of ipsilateral recurrent tumour on bronchial or parenchymal 
resection margin or hilar/mediastinal lymph nodes. Distant 
recurrence was defined as metastasis to other organs.
Our institutional review boards granted approval and 
waived the requirement for specific informed consent for 
this retrospective study.
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics 
20.0 software (SPSS Inc., Chicago, IL). Continuous 
variables are expressed as median, mean values ± SD and 
compared with unpaired t-test. Categorical variables 
were analysed using χ-square test. The variables resulting 
significant at the 0.20 level fed the multivariate regression 
model to identify predictive factors of evolution of NDN. 
The Kaplan-Meier method was used to calculate overall 
and DFS. OS was calculated from the date of operation to 
death or date of the last follow-up (31/03/2017); DFS was 
calculated for those patients who received resection from 
the date of operation to the date of the first evidence of 
recurrence. Differences in OS and DFS were determined by 
log-rank analysis. The impact of variables on OS and DFS 
was then evaluated by Cox multivariable hazard regression 
model using a significance as P<0.05.
Results
Patient demographics
Patient characteristics are summarized in Table 1 . 
Noteworthy, all patients were Caucasian and there was a 
slight predominance of men (53.2%).
Characteristics of the MC
The principal characteristics of the MC are depicted in 
Table 2. At pre-operative CT-scan, the MC had a mean 
maximal diameter of 25 mm (range, 6–100 mm) and in 40 
patients (85%) the MC was completely solid or part-solid.
Lung resections were performed through traditional 
thoracotomies or, more recently, thoracoscopic approach 
(25%), but always associated with hilar and mediastinal 
systematic node dissection.
Forty-two (89%) patients received an anatomic 
resection of the MC, including 31 lobectomies and 11 
segmentectomies, whereas only 5 patients were treated by 
wedge resections. 
Regarding the pathology of the MC, 44 patients had an 
invasive ADC, while 3 patients had either MIA (n=2) or AIS 
(n=1).
Nine patients (19%) underwent to a combination of 
more than one resection, in particular: 5 patients underwent 
lobectomy for MC with an ipsilateral wedge resection of a 
NDN and one underwent two segmentectomies of different 
lobes; multiple wedge resections were performed in three 
patients.
Of 9 patients who had an additional GGO removed along 
with the MC at first surgery, 4 GGOs were determined on 
pathology to be acinar ADC, 1 predominant lepidic ADC, 2 
MIAs, 1 AIS and AAH.
In total, 9 (19.1%) patients had all the lesions resected at 
first surgery while the remained 38 (80.9%) patients still had 
at least one GGO that was followed up by serial CT scan. 
Characteristics of the NDNs (Table 3)
The retrospective review of the CT scan showed a total of 
Table 1 Patients demographics
Characteristics Value







Never smokers 17 (36.2)
Former smokers 13 (27.6)
Current smokers 17 (36.2)
Cancer history 10 (21.3)
Other comorbidities
Hypertension 20 (42.5)
Heart disease 9 (19.1)
COPD 10 (21.2)
Diabetes mellitus 2 (4.2)
Other 3 (6.4)
Data are shown as mean ± SD [range] or number (percentage). 
SD, standard deviation; COPD, chronic obstructive pulmonary 
disease.
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Table 2 Radiological findings, operative strategy and pathological 
results of MC
Variable Value (n=47)
Pathological mean diameter in mm [range] 28±20 [10–100]




Wedge resection 2 (4.3%)
Combination 9 (19.1%)
Lobectomy + wedge 5 (10.6%)
Double segmentectomy 1 (2.1%)
Wedge resections 3 (6.4%)
Final pathology
Acinar ADC 25 (53.3%)
Papillary ADC 5 (10.6%)
Solid ADC 4 (8.5%)
Mucinous ADC 1 (2.1%)
ADC NOS 3 (6.4%)
Acinar + papillary ADC 1 (2.1%)
Lepidic + acinar ADC 1 (2.1%)
Lepidic ADC 3 (6.4%)
MIA 2 (4.2%)
AIS 1 (2.1%)










Patients with all lesions resected 9 (19.1%)
MC, main cancer;  GGO, ground-glass opacity;  ADC, 
adenocarcinoma; MIA, minimally invasive adenocarcinoma; AIS, 
adenocarcinoma in situ.
Table 3 Radiological findings, characteristics and post-surveillance 
treatment strategy of NDN
Variables Value
Total number of GGOs 102
Number of GGOs per patient [range] 2.17±1.90 [1–10]
CT dimension in mm [range] 15.00±8.46 [6–35]
Pathological dimension in mm [range] 18.63±14.31 [5–55]
Localization (n=47)
Ipsilateral lung 9 (19.1%)
Bilateral or contralateral 38 (80.9%)




More than one 17 (36.2%)
One 30 (63.8%)








Surgical procedure of evolved GGO (n=13)
Lobectomy + wedge 1 (6.3%)
Lobectomy 4 (25%)
Segmentectomy 1 (6.3%)
Wedge resection 7 (43.8%)
Pathology (n=13)
ADC acinar 3 (23.1%)
MIA 3 (23.1%)
ADC lepidic 1 (7.7%)
ADC NOS 1 (7.7%)
ADC mucinous 1 (7.7%)
ADC papillary 1 (7.7%)
ADC solid 1 (7.7%)
Adenosquamous 1 (7.7%)
AIS 1 (7.7%)
New onset GGOs (n=47) 7 (14.9%)
NDN, non-dominant nodules; GGO, ground-glass opacity; SBRT, 
stereotactic body radiation therapy; ADC, adenocarcinoma; 
MIA, minimally invasive adenocarcinoma; NOS, not otherwise 
specified; AIS, adenocarcinoma in situ.
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102 GGOs in the study population of 47 patients. Thirty 
(63.8%) patients had a single GGO lesion, whereas 17 
(36.2%) had multiple GGOs and the mean number of GGOs 
per patient was 2.17±1.90 (range, 1–10). The mean GGO 
lesion size was 15.00±8.46 mm (range, 6–35 mm) in the 
largest diameter at initial CT scan. Most of NDNs (80.9%) 
were located bilaterally or contralateral to the MC, while in 
only 19.1% of the cases they were ipsilaterally to the MC. 
Regarding the radiological aspect of the NDN, 36 
(76.6%) patients had a pGGO and 11 (23.4%) had a 
PSGGO. 
At the median follow-up of 41 months (range, 3– 
161 months), 16 (18%) out of 86 GGOs increased in size or 
developed a solid component, 4 (4.5%) lesions disappeared 
and 66 (77.5%) showed no change in size.  On a per-person 
basis, the frequency of progression of unresected GGOs was 
42% (16 of 38). In 13 patients (34%), there was growth of 
GGO with an average increase of 5 mm (range, 2–25 mm). 
Nine patients (23.6%) had at least one GGO that developed 
a solid component. All 7 PSGGO in observation evolved 
and required resection, while in 9 out of 31 (29%) patients 
the NDN with pGGO appearance evolved (HR =3.444; 
95% CI, 1.987–5.972; P=0.001). Among the 16 patients who 
showed GGO progression, 13 underwent surgical resection, 
two patients were treated by radiotherapy, with a median 
time to treatment of 19 months (range, 5–110 months), 
while one patient is still on follow-up, because there has 
been no further change in size. The final pathological 
analysis showed the presence of invasive ADC in 9 patients, 
MIA in 3 and AIS in 1; the two patients treated by SBRT 
did not undergo to histological confirmation. 
The only risk factor for evolution of the GGO, identified 
at univariate and confirmed at multivariable analysis, was 
the presence of a solid component at the initial CT scan 
(Table 4). In addition, during the follow-up new GGOs 
developed in 7 (14.9%) patients and five of them received 
treatment, including surgery in 3 cases and radiotherapy in 
2. The pathological examination of new nodules resected 
showed the presence of solid ADC, MIA and AAH.
Prognostic analysis and survival
OS rate at 3 and 5 years were 97.4% (Figure 1A). No factor 
had influence on OS at univariate and multivariable analysis 
(Table 5). 
Thirteen (27.6%) patients developed cancer recurrence, 
including 5 (38%) local recurrences, 7 (54%) distant 
recurrence and 1 (8%) both local and distant recurrence. 
DFS at 3 and 5 years were 82% and 66% respectively 
(Figure 1B).
Stage I of the MC, both on univariate and multivariable 
analysis, was the only prognostic factor of favourable DFS 
(HR =0.3; 95% CI, 0.089–1.015; P=0.049) (Table 5). 
The type (Figure 1C), the CT-scan initial diameter, the 
evolution of GGOs, the development of new GGOs, the 
multiplicity of GGOs, and if all the lesions were treated or 
not at the initial surgery, did not have any influence on OS 
and DFS (Table 5).
Discussion
In this study we evaluated the clinic-pathological features 
and long term outcomes of patients with a dominant 
invasive ADC in the setting of multifocal GGOs, in order 
to determine if there is a role for surgery and what can be 
the optimal management of residual and new developed 
lesions. We demonstrated that a totally Caucasian group 
of patients with an invasive lung ADC and additional 
GGOs (apparently multifocal lesions in the spectrum of 
ADC from AAH to invasive ADC) had favorable long 
term survival with surgery. The DFS of the patients was 
significantly associated with the stage of MC, whereas no 
association was observed between survival and the number 
or characteristics of additional GGOs, the emergence of 
new GGO or whether or not the GGOs required treatment 
because of their evolution during follow-up. Several studies, 
all from Asia and only one from USA have shown similar 
long term results. In a series of 23 Japanese patients with 
predominantly invasive ADC and other multifocal pure 
GGOs undergoing surgical resection, a 90% OS and 80% 
DFS was reported in a 5-year follow-up period (11). Similar 
long-term results (93% of 3-year OS rate and 78% of 3-year 
DFS rate) were described by Nakata (12) and also by Gu 
and co-workers, who, in 39 patients affected by a dominant 
ADC with multifocal GGOs, showed a mid-term DFS of 
95% (9). In the study from Shimada et al. (13) the survival 
of patients with multifocal GGOs was strongly affected 
by the radiological findings of the MC, with 5-year OS of 
95,8% and 68% when the MC had a CTR <0.5 or >0.5, 
respectively. These results are clearly better that those 
reported in patients with multifocal solid tumors (16,17), 
highlighting a possible difference in biology between 
a clinical situation of an invasive ADC with additional 
GGOs and multifocal solid invasive tumours. In the last 
case the possibility that some lesions could represent 
a lung metastasis cannot be excluded, if not in case of 
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Table 4 Univariate and multivariable analysis of risk factors influencing the evolution of GGOs
Variable
No GGO progression 
(n=22)




HR 95% CI P
Sex 1
Male 12 (54.5%) 9 (56.3%)
Female 10 (45.5%) 7 (43.8%)
Age (years) 70.68±6.542 71.19±6.337 0.813
Smoking history 0.238
Current smokers 8 (36.4%) 7 (43.8%)
Former smokers 8 (36.4%) 2 (12.4%)
Never smokers 6 (27.2%) 7 (43.8%)
Maximum diameter of MC 2.65±1.818 3.07±1.875 0.510
Final pathological histology of MC 0.601
ADC NOS 2 (9.1%) 1 (6.3%)
ADC papillary/acinar 0 1 (6.3%)
ADC acinar 13 (59.1%) 6 (37.5%)
ADC lepidic 1 (4.5%) 1 (6.3%)
ADC lepidic/acinar 0 1 (6.3%)
ADC mucinous 0 1 (6.3%)
ADC papillary 3 (13.6%) 2 (12.5%)
ADC solid 2 (9.1%) 2 (12.5%)
AIS 0 1 (6.3%)
MIA 1 (4.5%) 0
Pathological stage of MC 0.928
IA 11 (50.0%) 9 (56.3%)
IB 7 (31.8%) 3 (18.8%)
IIA 1 (4.5%) 1 (6.3%)
IIB 1 (4.5%) 1 (6.3%)
IIIA 2 (9.1%) 2 (12.5%)
Lymph node metastasis 3 (13.6%) 2 (12.5%) 1
Side of GGO respect to MC 1
Ipsilateral 2 (9.1%) 1 (6.3%)
Contralateral 20 (90.9%) 15 (93.8%)
Mean number of GGOs 2.14±1.754 2.00±2.251 0.835
GGO 0.729
Presence of one GGO 15 (68.2%) 12 (75.0%)
More than one GGO 7 (31.8%) 4 (25.0%)
Table 4 (continued)
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Table 4 (continued)
Variable
No GGO progression 
(n=22)




HR 95% CI P
Maximum diameter on CT scan of NDN 14.95±8.95 15.07±8.040 0.969
Pathological maximum diameter of NDN 1.47±0.935 2.46±16.100 0.428
GGO 0.001 3.444 1.987–5.972 0.001
Pure 22 (100.0%) 9 (56.3%)
Part-solid 0 7 (43.8%)
GGO, ground-glass opacity; MC, main cancer; ADC, adenocarcinoma; NOS, not otherwise specified; AIS, adenocarcinoma in situ; MIA, 
minimally invasive adenocarcinoma; NDN, non-dominant nodule.
Figure 1 (A) Overall survival curve; (B) disease-free survival curve; (C) survival curve in patients affected by pGGO and PSGGO. pGGO, 
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HR 95% CI P HR 95% CI P









NDN 0.531 0.098 0.3 0.066–1.363 0.119
Multiple 100% 90%
Single 100% 53.5%
Pathological stage of MC 0.246 0.040 0.3 0.089–1.015 0.049
I 100% 73%
II–IIIA 85.5% 30%
Lymph node metastasis 0.133 4.703 0.562–39.34 0.153 0.178 2.513 0.635–9.944 0.189
Presence 80% 60%
Absence 100% 68%
Completeness of resection 0.592
Resection of all lesions at first-
time surgery
100%
Un-resected lesions on follow-up 97%
Recurrence 0.008 144.1 0.23–92204 0.266
With 92%
Without 100%
Development of new GGOs 0.503 0.381
With 100% 44.2%
Without 96% 70.2%
Type of GGO 0.105 0.178 0.018–1.799 0.144 0.486
pGGO 96.3% 68.4%
PSGGO 100% 62.9%
Behaviour of GGO 0.662 0.804
Evolved NDN 100% 61%
Not evolved NDN 95.2% 70%
NDN, non-dominant nodule; MC, main cancer; GGO, ground-glass opacity.
4846
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2018;10(8):4838-4848jtd.amegroups.com
Bongiolatti et al. Surgical treatment of the dominant lung ADC associated with GGOs
different histology, while GGOs associated to a MC behave 
as a different kind of lung cancer that has a propensity 
for multifocal involvement but also less propensity to 
metastatize (18), making them good candidates for 
parenchymal sparing surgery with curative intent. All these 
data demonstrate that in case of an ADC with additional 
GGOs, prognosis is largely dependent on the characteristics 
and stage of MC and that there is a clear indication to 
surgery at least of the MC.  For this reason, the resection 
of the MC should be adequate in terms of radicality, but 
at the same time permitting to spare parenchyma in view 
of eventual future treatments. So, lobectomy and when 
possible segmentectomy (19), with simultaneous resection 
of ipsilateral accessible GGOs, if amenable to wedge, 
is the most appropriate surgical procedure as suggested 
by our data, because all GGOs simultaneously resected 
with the MC were pre-invasive or invasive form of ADC. 
This recommendation is based on the fact that some of 
these GGOs will evolve requiring future local treatment, 
that, in case of surgery, will be more complex (redo-
surgery) and sometimes more extensive compared to the 
initial procedure. On the other hand, in case of a central 
parenchymal pure GGO lesion that would require removal 
of a second lobe ipsilateral to the MC, and then possibly a 
pneumonectomy, we prefer to leave it, and like in case of 
contralateral GGOs, follow them for growth or invasiveness 
with serial CT scans. 
The appropriate surveillance strategy and eventual 
treatment for the residual or newly developed GGOs 
is still unclear. The chance of progression of a GGO 
over 2 to 5 years is quite variable depending on different 
background, but generally around 20–30%, although few 
lesions will require additional local treatment, because 
of their indolent nature (most are AIS with very few 
ADC) (9-11,13). In comparison to all these previous 
studies, we observed a higher percentage of evolution 
of GGO (42%) and consequently a major incidence of 
GGOs requiring resection. In total, 15 patients had their 
GGOs treated during the follow-up period because of 
the GGO progression. This result could be considered 
an overtreatment, since many of these lesions have been 
reported to correspond histologically to pre-invasive lesions 
or lepidic growing tumors with an indolent clinical course. 
However, in our study, 70% of resected specimens resulted 
to be an invasive ADC. This difference from previous 
studies is probably related to the fact that the initial mean 
size of the GGOs was larger in our study. The initial size 
of GGO lesion has been reported to be a predictive factor 
of future growth. Hiramatsu et al. (6) showed initial GGO 
size to be the strongest risk factor for future evolution with 
GGO growth incidence at 5 years of 66% when the GGOs 
are larger than 10 mm. In the study of Kim, although 
the overall malignancy rate was only 20%, the chance of 
malignancy was 67% for lesions larger than 10 mm (10). 
These observations suggest that larger GGOs are more 
likely to have an invasive character, and a high growth 
incidence can reasonably be expected. Two other studies 
(1,6) found that a previous history of lung cancer is a strong 
predictive factor of future growth of GGO, strengthening 
the concept that the context is very important, and the 
significance of GGOs in patients with a primary lung 
cancer is different from those detected in otherwise healthy 
individuals in a screening program. The reason for the 
higher growth incidence of GGOs in patients with a history 
of lung cancer is unclear. We can only speculate that it 
could be related to an alteration of the host, resulting 
in a favorable local microenvironment or in altered 
immunocompetence due to the presence of an invasive 
cancer. In our study, the only risk factor for evolution of 
the GGO was the presence of a solid component at the 
initial CT scan. Among 11 patients harboring PSGGOs, 
all 7 patients that we put on follow-up evolved. The other 
4 cases were operated, at first the surgery, concomitantly 
with the MC, demonstrating the presence at pathological 
examination of invasive ADC. In the long-term study of 
Sawada et al. dealing with 226 patients with GGO <3 cm 
in maximal diameter, invasive cancer was observed in only 
8% of the patients whose tumors increased in size during 
the follow-up and in up to 66,7% of patients with a CTR 
between 0.25 and 0.50 (20). Ohta et al. (5) showed that 
PSGGOs have a statistically significant higher Nm 23 and 
MIB1 expression compared to pGGOs, which support the 
hypothesis that PSGGOs represent relatively high-grade 
malignancy requiring prompt treatment. Considering the 
results of these reports and the present study, resection 
without a long follow-up period should be considered for 
PSGGOs. Thus, the radiographic features of GGOs are 
highly predictive of biologic behavior and are the most 
relevant criteria for intervention of a GGO, although, 
also other patients factors as age, estimated postoperative 
function and major comorbidities should be taken into 
consideration at the time of initial evaluation, for planning 
the more appropriate treatment. 
All studies dealing with this topic showed that some new 
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nodules have developed during the follow-up period. In 
Gu et al. one or more new GGOs developed in 41% of the 
patients, but only 1 required treatment during the study 
period (9). Instead, in our series only 7 (14.9%) patients 
developed new GGOs and 5 of 7 patients had their new 
lesions resected. This could be related to our longer follow-
up because it is likely that a higher percentage of the un-
resected or new GGOs would become clinically relevant 
over a long follow-up period.
The limitations of this study include all of the inherent 
biases proper to retrospective analyses with our cohort 
composed by selected patients. The presence of synchronous 
lung ADC associated with GGOs is still an infrequent 
situation in Western countries and we were still limited by 
this sample size and the resulting limited statistical power. 
In particular, we did not find any difference in OS between 
the groups due to the few events (deaths) observed. 
Nowadays, the molecular assessment of ADC (EGFR, 
ALK, ROS-1) is basilar for the treatment of advanced stage 
with TKI, but in our study, due principally to the long 
study period, the evaluation of biomarkers was not routinely 
determined in all patients.
In conclusion, patients affected by multiple synchronous 
lung ADC with GGO appearance enjoy good long-
term survival with anatomic resection of the MC, wedge 
resection of accessible ipsilateral GGOs and subsequent 
observation and resection of remaining evolving GGOs. 
This clinical scenario should not be considered as an 
advanced disease because both OS and DFS are favourable 
and not influenced by the new onset or evolution of GGOs. 
DFS is affected by the stage of the MC and then even those 
patients affected by characteristics of GGO requiring future 
treatment, such as part-solid GGOs, should not be denied 
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